🧾 What This Document Is

This is Mirion's definitive proxy statement (DEF 14A). It's an official notice and information packet sent to shareholders ahead of the company's annual meeting. Its main jobs are to tell shareholders what will be voted on, provide details about the company's leadership and pay, and explain how to vote.

👉 In short: This is your "homework packet" before a company's annual shareholder meeting. It tells you who's running the company, how much they get paid, and asks for your vote on key issues.

🏢 What The Company Does

Mirion Technologies (MIR) provides products and services that measure and manage radiation. They operate in two main areas:

• Nuclear Power: Safety instrumentation, software, and services for nuclear power plants.
• Medical (Cancer Care): Radiation detection equipment and medical imaging for hospitals and clinics.

Why it matters now: The CEO's letter highlights strong demand driven by two big trends: the need for power for AI/data centers (boosting nuclear energy) and an aging global population (increasing cancer care needs). They had a record $1+ billion in orders in 2025.

💰 Financial Highlights & Performance

The CEO letter notes strong momentum:

• Record Orders: $1+ billion booked in 2025, a 26% increase from 2024.
• Double-Digit Growth: Both the Nuclear Power and Nuclear Medicine segments saw double-digit organic revenue growth in 2025.
• Strategic Shift: The company acquired two companies (Certrec and Paragon Energy Solutions) to increase its exposure to the commercial nuclear power market. Pro-forma nuclear power revenue is now ~47% of total revenue, up from 37%.

🚀 Key Moves & Strategic Focus

The big story is Mirion's push into the booming nuclear power sector.

• Acquisitions: Bought Certrec (July 2025) and Paragon Energy Solutions (December 2025). These buys help them serve both large traditional reactors and new small modular reactors (SMRs).
• Why it matters: This is a direct bet on nuclear energy's role in powering data centers and AI. The company is intentionally shifting its business mix toward this high-growth area.

👥 Board of Directors & Governance

Shareholders are voting to elect eight directors for one-year terms. The board is proposed to include:

• Thomas D. Logan (CEO & Chairman)
• Kenneth C. Bockhorst (Lead Independent Director)
• Robert A. Cascella, Steven W. Etzel, Lawrence D. Kingsley, John W. Kuo, Jody A. Markopoulos, and Dr. Sheila Rege.

Why it matters: The board provides oversight. Seven of the eight nominees are deemed "independent." The mix includes experts in healthcare tech, industrial operations, finance, and law. Dr. Rege, a radiation oncologist, brings direct medical expertise relevant to Mirion's cancer care business.

💸 Executive Compensation (Say-on-Pay)

Shareholders are asked to approve, on an advisory basis, the compensation of the top executives ("Named Executive Officers").

• The document includes detailed tables showing the salary, bonuses, stock awards, and total compensation for each executive for 2025.
• The Compensation Discussion & Analysis (CD&A) section explains the philosophy: pay is meant to be performance-based, with a mix of cash and long-term equity (stock) to align executives' interests with shareholders'.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Strong market tailwinds in its key end markets (nuclear power, cancer care).
• Strategic acquisitions are reshaping the company toward higher-growth areas.
• Record order book indicates solid future demand.

⚠️ Risks & Considerations:

• Execution risk on integrating recent acquisitions.
• The company operates in highly regulated industries (nuclear, healthcare).
• The success of its nuclear power strategy depends on broader adoption of nuclear energy, which has long timelines and faces public/policy debates.

🔮 What's Next: The Annual Meeting

The 2026 Annual Shareholders' Meeting will be held virtually on:

• Date: Wednesday, May 13, 2026
• Time: 10:00 a.m. Eastern Time
• How to Attend/Vote: Via live webcast at www.virtualshareholdermeeting.com/MIR2026. You'll need your 16-digit control number.

Shareholders will vote on three proposals:

1. Elect the eight directors.
2. Ratify Deloitte & Touche LLP as the auditor.
3. Approve executive compensation (Say-on-Pay).

The Board recommends voting "FOR" on all three proposals.

🧠 The Analogy

Think of this proxy statement as a team's pre-game playbook and roster report before the big shareholder meeting. It shows you the game plan (strategy and performance), introduces the coaches and star players (board and executives), explains their contracts (compensation), and tells you how to vote on key plays (the proposals).

📇 Key Contacts & People

• CEO & Chairman: Thomas D. Logan
• Executive VP, Secretary & Chief Legal Officer: Emmanuelle Lee (Signatory of the notice)
• Investor Relations Email: [email protected]
• Corporate Secretary Address: Mirion Technologies, Inc., 1218 Menlo Drive, Atlanta, GA 30318

🧩 Final Takeaway

Mirion is capitalizing on strong demand in nuclear energy and cancer care, having just made major acquisitions to bet bigger on the nuclear power trend. This proxy statement asks shareholders to endorse the leadership team and their pay plan as they execute this growth strategy.